Project Grant R41AI148088

The National Institute of Child Health and Human Development (NICHD) awarded a $298,640 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to the University of Utah to develop and pilot test a mobile health application to support antimicrobial stewardship among rural healthcare providers in Bangladesh. The grant will fund the customization of an existing electronic clinical decision support tool into a comprehensive mobile application, called ADEPT, to guide the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,170 to Latde Diagnostics Corp., a woman-owned small business, to demonstrate the feasibility of a rapid, equitable antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal is to develop a lateral flow assay (LFA) that can detect bacterial growth and determine antibiotic susceptibility...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...

This National Institutes of Health (NIH) R21/R33 grant award in the amount of $734,360 aims to develop and validate an innovative, inexpensive multi-modal digital stethoscope capable of automated lung sound and respiratory rate analysis, with mobile phone interoperability to an electronic health (eHealth) platform for real-time lower respiratory infection (LRI) and antibiotic surveillance in low- and middle-income countries (LMICs). The grant, awarded under the NIH's Child Health and Human...

This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $991,832 to Astek Diagnostics Inc., a minority-owned small business, to develop a novel rapid antibiotic susceptibility testing (AST) platform. The project aims to deliver results in under one hour for various specimen types, including urine, cerebrospinal fluid, and wound effluent. This innovative platform is designed to quickly identify...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $585,794 to Tele-Stethoscope Inc., a self-certified small disadvantaged business, to develop a novel mobile phone technology for preeclampsia and hypertension detection. The project aims to demonstrate proof-of-concept that ordinary mobile phones can reproduce physicians' diagnoses of preeclampsia and accurately detect...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...

This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a transformative diagnostic platform by Resonantia Diagnostics, Inc. The platform aims to rapidly identify pathogens and determine their antimicrobial susceptibility within 60 minutes directly from patient samples. By enabling fast, evidence-based treatment decisions at the point of care, this innovation has the potential...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care (POC) molecular diagnostic assay for syphilis detection. The goal is to create a multiplexed genital ulcer disease (GUD) panel test that can rapidly and accurately diagnose syphilis, as well as other pathogens causing GUD, using giant magnetoresistive...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $766,877 to Albert Einstein College of Medicine to conduct a randomized controlled trial investigating the use of therapeutic drug monitoring (TDM) to prevent premature discontinuation of the antibiotic linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The study will enroll 280 participants...